Umbilical cord mesenchymal stem cells in idiopathic pulmonary fibrosis

Phase 1, open-label, single-arm trial of Xinbang mesenchymal stem cell injection in idiopathic pulmonary fibrosis (IPF), sponsored by Shanghai Life Science Technology. Primary endpoints: Tolerance of patients with idiopathic fibrosis to human umbilical cord mesenchymal stem cell injection at 4 weeks and Dose exploration of patients with idiopathic fibrosis to human umbilical cord mesenchymal stem cell injection at 4 weeks. Started Oct 2022; status: completed.